J&J's Marketing Of Risperdal For Children Slammed In Trial

Law360, Philadelphia (October 15, 2015, 6:32 PM EDT) -- Trial in a third case over abnormal breast growth allegedly caused by a Johnson & Johnson unit’s antipsychotic drug got underway on Thursday as a Philadelphia jury heard arguments that the pharmaceutical giant had worked to peddle the medication to pediatric doctors despite a lack of approval from federal regulators.

Kline & Specter PC attorney Tom Kline told the jury that improper marketing by Janssen Pharmaceuticals Inc. had led a pediatric neurologist to prescribe Risperdal to an 11-year-old boy to treat symptoms of Tourette dyndrome without...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.